) to identify full-term infants with and without a RSV diagnosis in the first year of life (RSV and non-RSV cohorts respectively). Infants were excluded if they had any of the following: prematurity (<37 weeks' gestation), low birth weight, small for gestational age, congenital heart or chronic lung disease, asthma or wheezing; or had received palivizumab. At least 2 years' continuous follow-up post birth was required throughout the ≤5-year follow-up period. RSV/non-RSV infants were 1:1 matched for gender, region and health plan type. Cumulative incidence of recurrent wheezing or asthma was identified by ICD-9/10 codes, through 1, 2, 3 and 4 years (Y)' post-index (1 year after birth) follow-up, and analyzed using conditional logistic regression.
Background. RSV is the main agent that causes Acute Lower Respiratory Tract Infection(ALRI) in children. Preterm infants(PT) have a higher risk of hospitalization and complications associated with RSV infection. The aim of this study was to describe epidemiology, clinical pattern and risk factors associated to RSV infection in PT infants.
Methods. Prospective, Cross-sectional study of patients admitted for ALRI, 2000-2017. Virological diagnosis was made by fluorescent antibody assay of nasopharyngeal aspirates or RT-PCR. We compared epidemiological and clinical features, complications and lethality between full term(FT) and PT infants. Logistic regression was performed to establish lethality risk factors in PT.
Results. A total of 15,451 patients included, 13,033 were tested and 45% (5,831) had positive samples; RSV was predominant (81.3%, 4, 738) all through the study period showing a seasonal epidemic pattern (May-July); 14% (655) were PT. Congenital cardiopathy OR = 3.41(1.12-10.3), P = 0.003 and perinatal respiratory history OR = 3.1(1.6-6.1), P < 0.001 were the independent predictors for VSR lethality in PT.
Background. Respiratory syncytial virus (RSV) is a major cause of pediatric morbidity and mortality worldwide. Appropriate case definitions are needed to accurately assess disease burden and evaluate novel RSV therapeutics and vaccines. Limited data exist on performance of RSV case definitions among young infants or in high-resource settings.
Methods. We used data collected on infants <6 months of age tested for RSV as part of routine clinical care at Children's Healthcare of Atlanta between January 2010 and December 2015. We evaluated sensitivity, specificity, positive (PPV), and negative predictive values (NPV) of clinical features, existing case definitions used by the World Health Organization (WHO), and alternative definitions we constructed using latent class analyses (LCA) to detect laboratory-confirmed RSV infection.
Results. Among 565 infants tested for RSV, 161 (28.5%) had laboratory-confirmed RSV infection. Among all case definitions evaluated, WHO-acute respiratory infection (ARI) ("cough or sore throat or shortness of breath or coryza, and a clinician's judgment that illness is due to infection") was the most sensitive [98.1%, 95% confidence interval (CI), 96.1-100.0, NPV 96.3%, 95% CI 92.2-100.0. The definition developed through LCA (cough and shortness of breath and coryza and wheeze and poor feeding and chest in-drawing) was the most specific (95.8%, 95% CI 93.8-97.8; PPV 51.4%, 95% CI 34.9-68.0).
Conclusion. The WHO ARI definition was the most sensitive for detecting laboratory-confirmed RSV infections among infants aged <6 months. However, alternative case definitions can confer higher specificity. Appropriate case definitions will vary depending on the content and setting in which they are utilized.
